Featured Research

from universities, journals, and other organizations

Testicular cancer risk tripled in boys whose testes fail to descend

Date:
November 29, 2012
Source:
BMJ-British Medical Journal
Summary:
Boys whose testes have not descended at birth -- a condition known as cryptorchidism -- are almost three times as likely to develop testicular cancer in later life, finds a new analysis.

Boys whose testes have not descended at birth -- a condition known as cryptorchidism -- are almost three times as likely to develop testicular cancer in later life, finds an analysis of the available evidence published online in Archives of Disease in Childhood.

The findings prompt the authors to ask whether boys with the condition should be regularly monitored to lessen the potential risk

Cryptorchidsim, where testes fail to descend into the scrotum and are retained within the abdomen, is the most common birth defect in boys, affecting around 6% of newborns.

The authors trawled the Embase and Medline databases for studies, which looked at the potential link between cryptorchidism as an isolated abnormality and testicular cancer risk, and which had been published between January 1980 and December 2010.

They found 735 relevant papers, published in English, among which 12 studies matched the inclusion criteria and covered corrective surgery (orchidopexy).

The haul included 9 case-control studies, involving 2281 cases of testicular cancer, which had been diagnosed between the ages of 15 and 75 between 1965 and 2006, and 4811 controls.

And it included 3 cohort studies, which regularly monitor similar groups of people over the long term to see what happens to them.

These studies involved more than 2 million boys whose health was tracked for a cumulative period of 58 million person years. Boys with cryptorchidism who developed testicular cancer totalled 345.

Boys with cryptorchidism in the case-control group were almost 2.5 times as likely to develop testicular cancer as those without the condition.

And those in the cohort studies were almost 4 times as likely to develop the disease if their testes had not descended at birth.

The authors calculated that, on the basis of the two sets of figures, boys with isolated cryptorchidism are almost three times as likely to develop testicular cancer in later life.

Testicular cancer is the most common cancer in men aged between 20 and 45, and rates have increased substantially worldwide over the past few decades, the authors point out.

In the UK, the number of new cases almost doubled between 1975-7 and 2006-8, rising from 3.4/100 000 men to 6.9/100 000.

"Many important unanswered questions remain, such as how laterality, degree of descent, and surgical correction affect the malignant potential of the [undescended] testis," write the authors.

And they add: "The most poignant question this study raises, however, is whether the risk of malignant transformation is sufficiently significant to warrant regular follow-up, as is the case with other premalignant states."


Story Source:

The above story is based on materials provided by BMJ-British Medical Journal. Note: Materials may be edited for content and length.


Journal Reference:

  1. S. Z. L. Lip, L. E. D. Murchison, P. S. Cullis, L. Govan, R. Carachi. A meta-analysis of the risk of boys with isolated cryptorchidism developing testicular cancer in later life. Archives of Disease in Childhood, 2012; DOI: 10.1136/archdischild-2012-302051

Cite This Page:

BMJ-British Medical Journal. "Testicular cancer risk tripled in boys whose testes fail to descend." ScienceDaily. ScienceDaily, 29 November 2012. <www.sciencedaily.com/releases/2012/11/121129093947.htm>.
BMJ-British Medical Journal. (2012, November 29). Testicular cancer risk tripled in boys whose testes fail to descend. ScienceDaily. Retrieved July 24, 2014 from www.sciencedaily.com/releases/2012/11/121129093947.htm
BMJ-British Medical Journal. "Testicular cancer risk tripled in boys whose testes fail to descend." ScienceDaily. www.sciencedaily.com/releases/2012/11/121129093947.htm (accessed July 24, 2014).

Share This




More Health & Medicine News

Thursday, July 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
China's Ageing Millions Look Forward to Bleak Future

China's Ageing Millions Look Forward to Bleak Future

AFP (July 24, 2014) China's elderly population is expanding so quickly that children struggle to look after them, pushing them to do something unexpected in Chinese society- move their parents into a nursing home. Duration: 02:07 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins